Jul 08, 09
|
| NEW STORY |
| 18:39 ET |
ChemoCentryx to Present at The 9th World Congress on Inflammation in Tokyo, Japan
|
|
Jun 01, 09
|
| 16:30 ET |
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
|
|
May 19, 09
|
| 08:00 ET |
ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
|
|
May 05, 09
|
| 08:30 ET |
ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
|
|
Oct 15, 08
|
| 08:00 ET |
ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
|
|
Jun 12, 08
|
| 08:30 ET |
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease
|
|
May 13, 08
|
| 08:00 ET |
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
|
|
Jan 17, 08
|
| 14:30 ET |
ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
|
|
Sep 26, 07
|
| 14:56 ET |
ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
|
|
Jul 24, 07
|
| 08:00 ET |
ChemoCentryx Achieves $5 Million Milestone from GlaxoSmithKline for Nomination of CCR1 Small Molecule Development Candidate
|
|
|